Practical Impact of the FDA Draft Guidance on Human Mass Balance Studies - A year of Client Discussions

In May 2022, the FDA announced new draft guidance on Human Mass Balance Studies​. Dr. Adam Robinson-Miller, Senior Manager 14C Enabled Drug Development at Quotient Sciences, shares his thoughts on their impact and clinical pharmacology considerations. Watch his presentation below and request a copy of the poster for added insight.